Therini Bio Secures $75M Series A to Advance First-in-Class Neuroimmune Therapies

Therini Bio, Inc. is excited to announce that the company has successfully raised $75,000,000 in its latest funding round, marking a significant milestone in its mission to develop first-in-class immunotherapies for neuroinflammation related to vascular dysfunction. As a clinical-stage biotech firm, Therini Bio is at the forefront of pioneering treatments aimed at selectively targeting toxic fibrin accumulation—a process that exacerbates neurodegeneration in conditions such as Alzheimer’s disease and Diabetic Macular Edema. The substantial investment will be strategically deployed to advance the company’s robust pipeline, enabling accelerated preclinical research and the timely transition into early-phase clinical trials. This funding injection reinforces the core scientific vision, a concept built on groundbreaking technology licensed from the esteemed laboratories of Dr. Katerina Akassoglou at the Gladstone Institutes, UCSF, and the former UCSD. Beyond bolstering research efforts, the capital is earmarked to expand collaborative partnerships, optimize development processes, and fortify regulatory pathways critical for transforming scientific discoveries into tangible clinical benefits. The round witnessed enthusiastic support from a prestigious group of life sciences investors, including the Alzheimer’s Drug Discovery Foundation, SV Health Investors’ Biotech Fund and Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, Merck & Co., Inc.’s therapeutics-focused corporate venture fund, and Sanofi Ventures. Such a diverse syndicate highlights the industry-wide confidence in Therini Bio’s strategic approach and its potential to reshape the treatment landscape for diseases characterized by detrimental neuroinflammation. With this capital boost, Therini Bio is poised to push forward innovative solutions that address unmet medical needs and ultimately improve patient outcomes.